Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies

NF-κB function in B lymphocytes

(2012) Mary Kaileh et al.   IMMUNOLOGICAL REVIEWS

Regulation of NF-κB by the CARD proteins

(2012) Changying Jiang et al.   IMMUNOLOGICAL REVIEWS

IKK biology

(2012) Fei Liu et al.   IMMUNOLOGICAL REVIEWS

Regulation of NF-κB by ubiquitination and degradation of the IκBs

(2012) Naama Kanarek et al.   IMMUNOLOGICAL REVIEWS

NF-κB regulation: lessons from structures

(2012) Gourisankar Ghosh et al.   IMMUNOLOGICAL REVIEWS

It takes two to tango: IκBs, the multifunctional partners of NF-κB

(2012) Michael Hinz et al.   IMMUNOLOGICAL REVIEWS

Regulation of NF-κB by deubiquitinases

(2012) Edward W. Harhaj et al.   IMMUNOLOGICAL REVIEWS

The noncanonical NF-κB pathway

(2012) Shao-Cong Sun   IMMUNOLOGICAL REVIEWS

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

(2011) T. L. Naylor et al.   CANCER RESEARCH

A20, ABIN-1/2, and CARD11 Mutations and Their Prognostic Value in Gastrointestinal Diffuse Large B-Cell Lymphoma

(2011) Gehong Dong et al.   CLINICAL CANCER RESEARCH

Selective Utilization of Toll-like Receptor and MyD88 Signaling in B Cells for Enhancement of the Antiviral Germinal Center Response

(2011) Baidong Hou et al.   IMMUNITY

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Analysis of the coding genome of diffuse large B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE GENETICS

Malt1-dependent RelB cleavage promotes canonical NF- B activation in lymphocytes and lymphoma cell lines

(2011) S. Hailfinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cleavage of NIK by the API2-MALT1 Fusion Oncoprotein Leads to Noncanonical NF- B Activation

(2011) S. Rosebeck et al.   SCIENCE

Mutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in primary CNS lymphoma

(2010) Manuel Montesinos-Rongen et al.   ACTA NEUROPATHOLOGICA

Early Events in B Cell Activation

(2010) Naomi E. Harwood et al.   Annual Review of Immunology

Oncogenic CARD11 Mutations Induce Hyperactive Signaling by Disrupting Autoinhibition by the PKC-Responsive Inhibitory Domain

(2010) Rebecca L. Lamason et al.   BIOCHEMISTRY

The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia

(2010) Y. Herishanu et al.   BLOOD

PI3K/p110  is a novel therapeutic target in multiple myeloma

(2010) H. Ikeda et al.   BLOOD

Classical and/or alternative NF- B pathway activation in multiple myeloma

(2010) Y. N. Demchenko et al.   BLOOD

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

(2010) A. Rinaldi et al.   BLOOD

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

(2010) Dinis Pedro Calado et al.   CANCER CELL

BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma

(2010) Jonathan Mandelbaum et al.   CANCER CELL

The Notch/Hes1 Pathway Sustains NF-κB Activation through CYLD Repression in T Cell Leukemia

(2010) Lluis Espinosa et al.   CANCER CELL

Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1

(2010) John P. Graham et al.   IMMUNOLOGICAL REVIEWS

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

(2010) Jia Ruan et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling

(2010) Su-Chang Lin et al.   NATURE

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells

(2010) B. Kloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Cytoskeleton Coordinates the Early Events of B-cell Activation

(2010) N. E. Harwood et al.   Cold Spring Harbor Perspectives in Biology

B Cell Signaling and Fate Decision

(2009) Tomohiro Kurosaki et al.   Annual Review of Immunology

The NF- B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas

(2009) U. Novak et al.   BLOOD

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas

(2009) K. Honma et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

(2009) J-F Rossi et al.   BRITISH JOURNAL OF CANCER

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

IRAK-4 Inhibitors for Inflammation

(2009) Zhulun Wang et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Mutations in the genes coding for the NF- B regulating factors I B  and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma

(2009) M. A. Schumacher et al.   HAEMATOLOGICA

Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas

(2009) R. J. Bende et al.   HAEMATOLOGICA

The Constant Region of the Membrane Immunoglobulin Mediates B Cell-Receptor Clustering and Signaling in Response to Membrane Antigens

(2009) Pavel Tolar et al.   IMMUNITY

The molecular assembly and organization of signaling active B-cell receptor oligomers

(2009) Pavel Tolar et al.   IMMUNOLOGICAL REVIEWS

Tyrosine kinases and their substrates in B lymphocytes

(2009) Tomohiro Kurosaki et al.   IMMUNOLOGICAL REVIEWS

Mutations ofNFKBIA, encoding IκBα, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases

(2009) Annette Lake et al.   INTERNATIONAL JOURNAL OF CANCER

TNFAIP3(A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma

(2009) Roland Schmitz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells

(2009) Uta Ferch et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Developmental Acquisition of the Lyn-CD22-SHP-1 Inhibitory Pathway Promotes B Cell Tolerance

(2009) A. J. Gross et al.   JOURNAL OF IMMUNOLOGY

A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma

(2009) E Chanudet et al.   LEUKEMIA

Casein kinase 1α governs antigen-receptor-induced NF-κB activation and human lymphoma cell survival

(2009) Nicolas Bidère et al.   NATURE

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

(2009) Mara Compagno et al.   NATURE

Frequent inactivation of A20 in B-cell lymphomas

(2009) Motohiro Kato et al.   NATURE

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma

(2009) S. Hailfinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression

(2008) H. Schmidlin et al.   BLOOD

Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis

(2008) Cornelia Hömig-Hölzel et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phospholipase C-γ2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen

(2008) Michele Weber et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20

(2008) Emre E. Turer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis

(2008) Verena Brune et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Protein Kinase C-Responsive Inhibitory Domain of CARD11 Functions in NF- B Activation To Regulate the Association of Multiple Signaling Cofactors That Differentially Depend on Bcl10 and MALT1 for Association

(2008) R. R. McCully et al.   MOLECULAR AND CELLULAR BIOLOGY

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling

(2008) Sivakumar Vallabhapurapu et al.   NATURE IMMUNOLOGY

Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK

(2008) Brian J Zarnegar et al.   NATURE IMMUNOLOGY

T cell antigen receptor stimulation induces MALT1 paracaspase–mediated cleavage of the NF-κB inhibitor A20

(2008) Beatrice Coornaert et al.   NATURE IMMUNOLOGY

The proteolytic activity of the paracaspase MALT1 is key in T cell activation

(2008) Fabien Rebeaud et al.   NATURE IMMUNOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compensatory IKK  activation of classical NF- B signaling during IKK  inhibition identified by an RNA interference sensitization screen

(2008) L. T. Lam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE

Essential Cytoplasmic Translocation of a Cytokine Receptor-Assembled Signaling Complex

(2008) A. Matsuzawa et al.   SCIENCE

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma

(2007) L. T. Lam et al.   BLOOD

TNFAIP3is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma

(2007) Keiichiro Honma et al.   GENES CHROMOSOMES & CANCER

Molecular Basis for the Unique Deubiquitinating Activity of the NF-κB Inhibitor A20

(2007) Su-Chang Lin et al.   JOURNAL OF MOLECULAR BIOLOGY